Condition: CD19-positive Relapsed or Refractory B-cell Malignancies · Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd.
This study is designed for exploring the preliminary safety and efficacy of the recombinant allogeneic healthy γδT cells transduced with the anti-CD19 lentiviral vector in patients with CD19-positive B cell hematolymphatic malignancies.
This description comes directly from the study's public registry record.
Xingbing Wang, MD · 13856007984 · wangxingbing@ustc.edu.cn
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of USTC (AnHui Provincial Hospital) | Hefei, Anhui, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06092047